Researchers in South Korea are making progress on a peptide-based eye drop formulation aimed at treating macular degeneration, a leading cause of vision loss, without relying on the injections that are currently the standard of care. If successful, this approach could transform how patients manage this common eye condition.
Macular degeneration, particularly the “wet” form, is typically treated with anti-VEGF injections delivered directly into the eye at regular intervals, often monthly. While effective, these injections can be uncomfortable, require clinical visits, and may discourage some patients from maintaining consistent treatment schedules. A topical peptide-based alternative delivered via eye drops would represent a major shift toward more patient-friendly care.
The peptide technology at the center of this development is designed to target the same underlying biological pathways involved in abnormal blood vessel growth in the eye, which is a hallmark of wet macular degeneration. By formulating the peptide for topical delivery, researchers hope to achieve therapeutic effects while bypassing the need for injections altogether, potentially improving comfort and treatment adherence for patients.
This advancement reflects a broader trend in peptide science, where researchers are increasingly exploring ways to deliver peptide therapeutics through non-invasive routes, including topical, oral, and inhaled formulations. Eye drops, in particular, offer a promising avenue because they can achieve localized delivery directly to the affected tissue, potentially reducing systemic exposure compared to injections.
While more research and clinical validation will be needed before such a treatment becomes widely available, the progress being made in Korea highlights the continued innovation happening in peptide-based ophthalmology. Patients and clinicians alike may one day benefit from a simpler, less invasive way to manage a condition that affects millions of people worldwide as they age.
This article is for informational purposes only and is not intended as medical advice.
Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.
Source: Korean peptide eye drops advance to replace injections for macular degeneration – Chosunbiz
Leave a Reply